Novartis ends mid-stage IPF trial, will keep testing drug in PAH

Novartis has terminated a mid-stage trial of an oral treatment candidate for idiopathic pulmonary fibrosis, the company confirmed to Endpoints News.

The Swiss pharma giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Researchers identify new blood marker for dopamine system damage

The marker in question is called DOPA decarboxylase (DCC). In the current study, DCC was found to be elevated in individuals with Parkinson’s disease as

September 19, 2023

MSD snags European approval for pulmonary arterial hypertension therapy – Pharmaceutical Technology

MSD’s Winrevair has been approved to treat pulmonary arterial hypertension (PAH), a disorder which is caused by high blood pressure in the lungs. Credits: MMD

August 26, 2024

PharmaTher Holdings Provides Corporate Update – Psychedelic Alpha

Company funded to meet upcoming milestones over the next 24 months Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.